FDA Grants Priority Review to Genentech’s Tecentriq for Stage III Colon Cancer
Event summary
- FDA accepted Genentech’s sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer.
- Priority Review designation sets FDA decision deadline for October 9, 2026.
- ATOMIC study showed 50% reduction in disease recurrence or death compared to chemotherapy alone.
- Tecentriq plus FOLFOX6 achieved 36-month disease-free survival of 86% vs. 76% with chemotherapy alone.
The big picture
Genentech’s Tecentriq, already approved for multiple aggressive cancers, is now poised to redefine adjuvant therapy for stage III colon cancer. The FDA’s Priority Review underscores the unmet need in this high-relapse population, where 30% of patients experience recurrence within five years. If approved, Tecentriq could become a cornerstone treatment, leveraging its proven efficacy in high-mutation-rate tumors. This move aligns with broader trends in precision oncology, where immunotherapy is increasingly tailored to specific tumor biomarkers.
What we're watching
- Regulatory Success
- Whether the FDA approval will solidify Tecentriq’s role in early-stage colon cancer treatment.
- Market Expansion
- How Genentech will position Tecentriq against competitors in the adjuvant colon cancer space.
- Clinical Adoption
- The pace at which oncologists integrate Tecentriq into standard care for dMMR/MSI-H colon cancer.
Related topics